ADC Therapeutics SA (ADCT) Institutional Ownership

Ownership Summary

ADC Therapeutics SA (NYSE:ADCT) currently has 104 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The collective stake of institutional investors in ADC Therapeutics moved to 60.6% in September 2025, a shift down from the 68.9% reported for June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by -0.85%, with a year-over-year an increase of 36.84% in the count of filers.
• Among the 104 institutional holders of ADC Therapeutics, 47 added to their stakes while 29 trimmed their positions and 28 held steady.
• This class of investors decreased its holdings in ADC Therapeutics to 68.17Mn shares for the 13F-cycle ending September 2025, down by 587.63K shares quarter on quarter, and up 13.53Mn shares year over year.
• The top institutional stake in ADC Therapeutics as of September 30, 2025 belongs to Redmile Group, LLC, which owns 15.67Mn shares, or 13.93% of the company.
• Among the most significant buyers of ADC Therapeutics during September 2025 were TCG Crossover Management, LLC (1.39Mn), Lynx1 Capital Management LP (1.33Mn), CITADEL ADVISORS LLC (779.28K), Opaleye Management Inc. (682.53K), MORGAN STANLEY (623.49K).
• Leading sellers of ADC Therapeutics stock in September 2025 included Prosight Management, LP (3.00Mn), HEIGHTS CAPITAL MANAGEMENT, INC (2.18Mn), BANK OF AMERICA CORP /DE/ (837.77K), UBS Group AG (565.31K), Walleye Capital LLC (336.59K).
• The top 10 institutional holders of ADC Therapeutics for the quarter ending September 2025 included Redmile Group, LLC (15.67Mn), Point72 Asset Management, L.P. (8.14Mn), Prosight Management, LP (7.47Mn), ORBIMED ADVISORS LLC (5.91Mn), BlackRock, Inc. (4.51Mn), MORGAN STANLEY (3.67Mn), Nantahala Capital Management, LLC (2.27Mn), GOLDMAN SACHS GROUP INC (1.59Mn), TCG Crossover Management, LLC (1.39Mn), BANK OF AMERICA CORP /DE/ (1.36Mn).